Patient characteristics in the training and validation cohorts
| . | Training (PRIMA) (n = 1135), N (%) . | Validation (FL2000+MER) (n = 479), N (%) . |
|---|---|---|
| Age >60 y | 402 (35) | 225 (47) |
| Male sex | 590 (52) | 261 (54) |
| ECOG >1 | 49 (4) | 24 (5) |
| β2m >3 mg/L | 341 (30) | 163 (34) |
| Stage III-IV | 1026 (90) | 388 (81) |
| Nodal sites involvement >4 | 639 (56) | 211 (44) |
| Bone marrow involvement | 635 (56) | 238 (50) |
| Extranodal sites involvement (other than bone marrow) | 598 (53) | 169 (35) |
| LDH > UNL | 378 (33) | 139 (29) |
| Hemoglobin <12 g/dL | 239 (21) | 91 (19) |
| B symptoms* | 363 (32) | |
| LoDLIN >6 cm* | 508 (45) | |
| Effusion syndrome* | 150 (13) | |
| Compression syndrome* | 208 (18) | |
| Circulating malignant cells* | 92 (9) | |
| Platelets <150 × 109/L* | 181 (16) | |
| Albumin <40 g/L* | 301 (33) | |
| Induction treatment | ||
| R-CHOP | 840 (74) | 121 (25) |
| R-CVP | 253 (22) | 68 (14) |
| R-FCM | 42 (4) | 0 (0) |
| R-bendamustine | 0 (0) | 104 (22) |
| R-CHVP+IFN | 0 (0) | 175 (37) |
| Others | 0 (0) | 11 (2) |
| Maintenance† | ||
| Rituximab | 489 (50) | 95 (20) |
| IFN | 0 (0) | 175 (36) |
| None | 485 (50) | 209 (44) |
| . | Training (PRIMA) (n = 1135), N (%) . | Validation (FL2000+MER) (n = 479), N (%) . |
|---|---|---|
| Age >60 y | 402 (35) | 225 (47) |
| Male sex | 590 (52) | 261 (54) |
| ECOG >1 | 49 (4) | 24 (5) |
| β2m >3 mg/L | 341 (30) | 163 (34) |
| Stage III-IV | 1026 (90) | 388 (81) |
| Nodal sites involvement >4 | 639 (56) | 211 (44) |
| Bone marrow involvement | 635 (56) | 238 (50) |
| Extranodal sites involvement (other than bone marrow) | 598 (53) | 169 (35) |
| LDH > UNL | 378 (33) | 139 (29) |
| Hemoglobin <12 g/dL | 239 (21) | 91 (19) |
| B symptoms* | 363 (32) | |
| LoDLIN >6 cm* | 508 (45) | |
| Effusion syndrome* | 150 (13) | |
| Compression syndrome* | 208 (18) | |
| Circulating malignant cells* | 92 (9) | |
| Platelets <150 × 109/L* | 181 (16) | |
| Albumin <40 g/L* | 301 (33) | |
| Induction treatment | ||
| R-CHOP | 840 (74) | 121 (25) |
| R-CVP | 253 (22) | 68 (14) |
| R-FCM | 42 (4) | 0 (0) |
| R-bendamustine | 0 (0) | 104 (22) |
| R-CHVP+IFN | 0 (0) | 175 (37) |
| Others | 0 (0) | 11 (2) |
| Maintenance† | ||
| Rituximab | 489 (50) | 95 (20) |
| IFN | 0 (0) | 175 (36) |
| None | 485 (50) | 209 (44) |
Missing data: for the training cohort: β2m (n = 85), bone marrow involvement (n = 34), LDH (n = 5), LoDLIN (n = 7), effusion syndrome (n = 23), circulant malignant cells (n = 122), platelets (n = 1), albumin (n = 223); for the validation cohort: ECOG (n = 4), β2m (n = 11), stage (n = 8), nodal sites (n = 21), bone marrow involvement (n = 24), extranodal sites (n = 9), LDH (n = 26), hemoglobin (n = 16).
IFN, interferon; LoDLIN, longest diameter of the largest involved node; UNL, upper normal limit.
Data not extracted in the validation cohort.
Only responding patients could be eligible for maintenance therapy.